Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest developments in targeting non-G12C KRAS mutations in the treatment of non-small cell lung cancer (NSCLC). This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть